Background
A regional health plan with approximately 280,000 covered lives had a mature pharmacy rebate program but had never systematically pursued rebate recovery on the medical benefit side. Specialty biologics and physician-administered drugs — infused oncology agents, high-cost immunology therapies, and other Part B-eligible products — were being processed and paid, but the rebate reconciliation infrastructure for those claims didn't exist.
The plan's finance team had flagged the gap during an annual audit. The question wasn't whether rebates were theoretically available — manufacturer programs for these products were known to exist — it was whether the claims data was organized well enough to support a recovery process and whether the effort required to build that process was worth pursuing given other priorities.
Medical benefit drug claims lacked the structured identifiers and validation layer needed to support rebate submissions. Without a reconciliation process, the plan had no way to verify what it was owed, let alone collect it.
What VativoRx Did
VativoRx began with a claims data audit covering 24 months of medical benefit drug spend. The process involved identifying all claims with qualifying NDC and J-code combinations, normalizing the data against manufacturer contract terms, and building a reconciliation layer that could be updated on a rolling basis going forward.
The initial audit surfaced significant undercollection across three therapeutic categories: oncology supportive care, immunology, and rare disease biologics. In each category, the plan had been paying contracted rates but had not been systematically capturing the rebate layer that sits above those rates under manufacturer GPO and direct-contract arrangements.
"We had always assumed the medical benefit side was too complex to be worth the effort. The first reconciliation report changed that assumption completely."
The Recovery Process
Working from the reconciliation baseline, VativoRx submitted retroactive rebate claims covering the 18-month lookback period allowed under the relevant manufacturer agreements. The submission process required coordinating documentation across multiple therapeutic categories and manufacturer contacts simultaneously.
First payments were received within 90 days of initial submission. The complete 18-month recovery settled at $2.3M across 14 manufacturer relationships. Going forward, the plan established a quarterly rebate reporting cycle using the same reconciliation infrastructure, projecting an ongoing annual recovery of approximately $900K based on current claim volume.
Documentation and Compliance
Throughout the process, VativoRx maintained claim-level documentation supporting each rebate submission. For a plan operating in a regulated environment, auditability matters as much as recovery. Every submitted claim was traceable to the underlying medical benefit record, the applicable contract term, and the supporting clinical coding — ensuring the recovery held up under internal audit review.
The plan's compliance team reviewed the complete documentation package before any submissions were finalized. No claims were submitted without a clear evidentiary basis under the applicable contract language.
What Changed Going Forward
The outcome wasn't only the $2.3M recovery. The health plan now has a functioning medical benefit rebate program operating alongside its pharmacy program — something it didn't have before. The claims reconciliation infrastructure built during the initial engagement continues to run on a quarterly cycle, and the plan's finance team has incorporated medical benefit rebate projections into its annual budget model for the first time.
The six-week timeline from engagement start to first reconciliation report was faster than the plan's internal team had estimated for a comparable build. That timeline was possible because VativoRx brought the process framework, the manufacturer relationships, and the claims normalization methodology — the plan's team provided the claims data and contract access.
Client identifying details have been generalized to protect confidentiality. Financial outcomes reflect this specific engagement and are not a guarantee of comparable results. Individual results depend on claim volume, contract terms, and the specific rebate programs available to a given organization.
Get the full case study
Subscribe to receive access to all VativoRx case studies, industry analyses, and rebate management resources.
No credit card required · Unsubscribe anytime